Navigation Links
Prostate Cancer Patients at Higher Risk of Blood Clots
Date:4/14/2010

Dangers were greatest for those on hormone therapy, study found

WEDNESDAY, April 14 (HealthDay News) -- Men with prostate cancer are at greater risk for developing blood clots, especially if they're undergoing hormone therapy, new research shows.

"Our findings indicate that it is important to consider thromboembolic [blood-clotting] side effects when treating patients with prostate cancer, especially those who require endocrine treatment," said Mieke van Hemelrijck, lead author of a study in the April 13 online issue of The Lancet Oncology.

Still, the findings shouldn't change the way men with this type of tumor are treated, just perhaps the way they are monitored, van Hemelrijck added.

"Endocrine treatment is currently the cornerstone of therapy for men with locally advanced or metastatic disease. It is thus not possible to change the treatment, but doctors can be more aware of the risk of thromboembolic diseases and check for certain symptoms when following up their patients," said van Hemelrijck, who is a doctoral candidate at Kings College London.

And the findings do give an extra round of reassurance that this is indeed a risk, another expert noted.

"We have known for decades that cancer patients have a greater risk of blood clots, [but] it hasn't been as well-defined in the prostate cancer population," said Dr. Steven Clinton, director of prostate and genitourinary oncology at The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute in Columbus. "For the first time, this puts some numbers on the risk in that population. It's an enormous study, and it does give us some numbers to work with."

According to background information in the study, cancer patients in general have about a fourfold greater risk of developing blood clots than people who are cancer-free.

Advancing age and other treatments for cancer, including prostatectomy or removal of the prostate gland, might further elevate that clotting risk.

These authors analyzed data from Sweden's National Prostate Cancer Register, which includes 96 percent of all prostate cancer cases in that country. Men were divided into three groups: those receiving endocrine or hormone therapy to reduce levels of male hormones (including testosterone), those receiving surgery and/or radiation and those who were simply being watched.

Men taking hormone therapy had a 2.48 increased risk of developing a blood clot and almost double the chance of a pulmonary embolism (when the clot travels to the lung), compared to men without prostate cancer.

Those in the prostatectomy group had a 73 percent increased risk of blood clots and double the risk of a pulmonary embolism. Those in the "watch-and-wait group had a 27 percent increased risk of blood clots and a 57 percent increased risk of that clot moving to the lung.

None of the groups saw an increased risk of arterial embolism, when clots block an artery.

Those under the age of 65 and those with more advanced disease had even more risk. Given that men in the no-treatment-yet group also had more blood clots, much of the risk was likely from the cancer itself.

"This is probably telling us that something about the cancer and its biology may be impacting coagulation," Clinton said.

However, the type of treatment obviously also plays a role.

Still, the absolute number of blood clots seen in the study was relatively low -- about four per 1,000 person-years, up from 2.

"One should be aware of [the increased risk] and make sure that that the patient is being monitoring for symptoms of blood clots but you're not going to go so far as to recommend that we give [blood thinners] to everybody to prevent it," Clinton said.

More information

The National Cancer Institute has more on prostate cancer.



SOURCES: Mieke Van Hemelrijck, doctoral candidate, Kings College London; Steven Clinton, M.D., Ph.D., director, prostate and genitourinary oncology, Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus; April 13, 2010, The Lancet Oncology


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Registration Now Open for Little Red Door's Unite 2 Fight Race Against Prostate Cancer Saturday, July 10, 2010
2. New investigation supports correlation between XMRV and prostate cancer
3. Drug reduces risk of prostate cancer diagnosis in high-risk men
4. Study Revives Debate on Prostate Drug
5. Prostate Cancer Treatment Database Hits Milestone of 12,500
6. Male Infertility Significantly Increases Risk of Prostate Cancer
7. Infertility Raises Risk of More Aggressive Prostate Cancer
8. Infertility increases a mans risk of prostate cancer
9. Prostate Cancer Radiation Side Effects May Subside With Time
10. Increased radiation dose does not increase long-term side effects for prostate cancer patients
11. Freezing Tumors Shows Promise Against Prostate, Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... The IoT (Internet of Things) is ... making a huge impact on businesses and individual consumers alike. Laboratories can maximize ... have a value anywhere from $4 trillion to $11 trillion dollars by the year ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... serving the families and businesses of the Norwalk and Vermillion areas, celebrates ... Recovery Center (N.O.R.A.) is a nonprofit, community-based substance abuse prevention and peer ...
(Date:3/23/2017)... ... 23, 2017 , ... The StayWell Company announced today that ... covers StayWell’s asthma, coronary artery disease, congestive heart failure, chronic obstructive pulmonary disease, ... excellent programs for the delivery and improvement of disease management and that meet ...
(Date:3/23/2017)... ... ... The TouchPoint Solution, home of Buzzies *, is boosting the Arizona economy ... change the way we interact with stress and live our day-to-day lives,” said Dr. ... December 2016, The TouchPoint Solution has sold more than $750,000 in product sales. The ...
(Date:3/23/2017)... ... 23, 2017 , ... After raising more than $1.135 million ($1,479,231 AUD) from ... pillow in crowdfunding history, has established a U.S. Headquarters in New York City, ... Americans. , “We’re excited to be operating on U.S. shores, where most of our ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... March 23, 2017 Ascendis Pharma A/S (Nasdaq: ... technology to address significant unmet medical needs in rare ... conference call and webcast on Monday, April 3 during ... in Orlando, Florida , to discuss ... (TransCon Growth Hormone, TransCon PTH and TransCon CNP). ...
(Date:3/23/2017)... 2017 /PRNewswire/ - INVICTUS MD STRATEGIES CORP. ("Invictus MD" ... MD announces that AB Laboratories Inc. ("AB Labs") has ... facility under the Access to Cannabis for Medical Purposes ... . The facility, which was licensed ... currently operating at half capacity, with full production capacity ...
(Date:3/23/2017)... 2017 The global reprocessed ... the top five players accounting for nearly 94% ... are Stryker Sustainability Solutions, Ethicon (Johnson & Johnson), ... VANGUARD AG. Despite the high level of consolidation, ... the prevalence of fierce competition among the key ...
Breaking Medicine Technology: